Full-Time

Principal Image Processing Engineer

Confirmed live in the last 24 hours

Calyxo

Calyxo

51-200 employees

Develops medical devices for kidney stone treatment

Compensation Overview

$190k - $250k/yr

+ Stock Options + Employee Benefits Package

Expert

No H1B Sponsorship

Pleasanton, CA, USA

Category
Applied Machine Learning
Computer Vision
AI & Machine Learning
Required Skills
Python
CUDA
Machine Learning
MATLAB
Risk Management
C/C++
FPGA
Requirements
  • MS in Electrical Engineering, Computer Science, Optical Engineering or a related technical field. PhD strongly preferred.
  • 10+ years of related experience in medical device product development, with 7+ years in the sub-field of endoscope image signal pipeline design.
  • Deep technical expertise in real-time camera image processing algorithms, including debayering, non-uniformity correction, color correction, noise reduction, contrast enhancement and 3A. Expertise in machine learning-based image processing preferred.
  • Advanced knowledge of CMOS image sensor hardware operation and electronic video/control signal interfaces (e.g. MIPI, I2C, SPI etc).
  • Experience performing quantitative image and video quality analyses via industry-standard methodology, including colorimetry.
  • Expertise in video standards and display technologies/interfaces.
  • Familiarity with latest-generation embedded real-time imaging platforms (FPGAs, SoCs, GPUs, embedded processors, etc).
  • Required SW skills: C/C++ (CUDA), Python, MATLAB.
  • Experience leading external vendors and contract manufacturers in the development of custom imaging solutions
  • Exceptional problem-solving skills and experience leading multifunctional technical project teams through all development lifecycle phases
  • Experience in IEC 60601 for medical devices or any other regulatory environment such as automotive or aerospace.
  • Experience in requirements definition, design reviews, change management and risk control
  • Excellent technical writing and verbal communication skills are a must. Presentation capabilities that can be tailored anywhere from team-level to executive-level are essential.
  • Ability to work independently or in team setting required.
  • Must be self-directed, self-motivated and be able to multi-task in a fast-paced environment with multiple priorities.
  • Experience and involvement with MDRs, IDEs, and 510(k) filings is required.
  • Knowledge and ability to interpret and follow applicable regulations, guidelines, and policy statements is required. Must have experience working under quality systems designed to meet governmental regulations such as FDA QSR, ISO 13485, and the MDD.
  • Ability to travel domestically and internationally up to 10% of the time.
Responsibilities
  • Develop state-of-the-art vision firmware/software image signal pipeline algorithms for endoscopic visualization.
  • Work with cross-functional teams to define requirements for image and video quality.
  • Work with clinical engineering and product management to translate user feedback on visualization quality into ISP algorithm improvements.
  • Work with program management to define release content.
  • Organize design reviews to ensure coherent design across hardware, firmware and software interfaces.
  • Create change orders, test protocols/reports and design documents.
  • Complete Design Verification testing and risk management activities.
  • Interact with suppliers and internal operations representatives to perform root cause investigation, component lifecycle management and continuous improvement.
  • Contribute to the technology roadmap for visualization and related research endeavors.
  • Contribute to a culture of continuous improvement and innovation among engineering and cross-functional teams.
  • Collaborate with cross-functional teams to bring prototypes to the market.
  • Mentor junior and non-specialist engineering talent, promoting a collaborative and high-performance work environment.
Desired Qualifications
  • MATLAB/Simulink-based HDL generation experience (AMD Vitis Model Composer and/or DSP Builder) preferred.

Calyxo develops medical devices specifically designed to treat kidney stones. Their products focus on improving the effectiveness and safety of treatment options available to urologists. By collaborating with leading urologists, Calyxo ensures that their devices meet the real clinical needs of healthcare providers. Unlike many competitors, Calyxo emphasizes a strong partnership with medical professionals to enhance patient care and clinical outcomes. The company's goal is to provide advanced solutions that enable urologists to treat kidney stones more efficiently, ultimately improving the overall experience for patients.

Company Size

51-200

Company Stage

Series D

Total Funding

$97.2M

Headquarters

Pleasanton, California

Founded

2016

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA clearance for the redesigned CVAC System boosts market credibility and adoption.
  • Rising prevalence of kidney stones expands Calyxo's potential customer base.
  • Series D funding of $50M supports further innovation and market expansion.

What critics are saying

  • Emerging competition may impact Calyxo's market share in kidney stone treatments.
  • Economic downturns could reduce healthcare spending on new medical devices.
  • Rapid technological advancements require Calyxo to continuously innovate to stay competitive.

What makes Calyxo unique

  • Calyxo's CVAC System offers superior stone clearance compared to standard URS.
  • The company focuses on minimally invasive kidney stone treatments with high patient satisfaction.
  • Calyxo collaborates with leading urologists to enhance R&D and device innovation.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Stock Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

1%

2 year growth

-7%
Business Wire
May 14th, 2024
Study Presented At Aua Shows Superior Kidney Stone Clearance Rates For Sure Procedure Using Calyxo’S Cvac System Vs Standard Urs

PLEASANTON, Calif.--(BUSINESS WIRE)--Calyxo, Inc., a medical device company developing innovative solutions for patients with kidney stones, has announced that positive study results for its CVAC System were presented last week at the American Urological Association (AUA) Annual Meeting in San Antonio. The CVAC System, a revolutionary technology that is designed for complete kidney stone removal, was the focus of the prospective, randomized, multi-center ASPIRE study, which compared the safety and efficacy of steerable ureteroscopic renal evacuation (SURE) vs ureteroscopy (URS) with basketing. The 30-day results of the ASPIRE study were presented at the AUA Meeting by urologist Thomas Chi, MD of the University of California, San Francisco. In 101 patients, SURE demonstrated statistically superior stone clearance and significantly lower residual stone volume compared to standard URS. Unlike standard URS, the CVAC System achieved these results independent of baseline stone burden. Safety was comparable between groups

Business Wire
Mar 26th, 2024
Calyxo Announces Fda Clearance For New, Redesigned Cvac System

PLEASANTON, Calif.--(BUSINESS WIRE)--Calyxo, Inc., a medical device company developing innovative solutions for patients with kidney stones, announced that it has received FDA clearance for its new, redesigned CVAC System, which enables a minimally invasive approach to kidney stone treatment. More than 50 procedures have already been completed by 12 urologists with the new CVAC System, yielding strong patient outcomes and consistently positive physician feedback. Clinical studies have shown that residual stone fragments are associated with a 20%-44% incidence of post-procedure problems, including pain, infection, emergency department visits, hospitalization and need for retreatment. Steerable ureteroscopic renal evacuation (SURE) using the original CVAC Aspiration System has been used to successfully treat more than 1,500 patients in the U.S., demonstrating that vacuum aspiration of stone fragments improves clinical outcomes, with 97% volumetric stone clearance and a high likelihood of avoiding the need for a secondary or more invasive procedure (according to clinical study data collected in patients treated with the device)

Finsmes
Dec 12th, 2023
Calyxo Raises $50M in Series D Funding

Calyxo, a Pleasanton, CA-based medical device company developing next-generation treatment solutions for patients with kidney stones, raised $50M in Series D funding.

Questa Capital
Jul 6th, 2022
Questa Capital invests into Calyxoinc in $32.7M

Calyxo, Inc., a medical device company focused on improving care for patients with kidney stones by delivering next generation treatment solutions, has announced the closing of a $32.7 million Series C financing round led by Questa Capital and CRG.

Business Wire
Jul 6th, 2022
Calyxo Raises $32.7 Million In Series C Financing To Support Novel Approach To Treating Kidney Stones

PLEASANTON, Calif.--(BUSINESS WIRE)--Calyxo, Inc., a medical device company focused on improving care for patients with kidney stones by delivering next generation treatment solutions, has announced the closing of a $32.7 million Series C financing round led by Questa Capital and CRG. Calyxo has developed the innovative CVAC Aspiration System that utilizes irrigation and aspiration to remove kidney stones with the goal of a surgically stone-free outcome, a challenge that has always been difficult to achieve consistently